|
|
Volumn 25, Issue 5, 2014, Pages 371-374
|
|
The European Medicines Agency approval of 5-aminolaevulinic acid (Ameluz) for the treatment of actinic keratosis of mild to moderate intensity on the face and scalp: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use
a
|
|
Author keywords
5 aminolaevulinic acid; Actinic keratosis; Ameluz; European Medicines Agency
|
|
Indexed keywords
AMINOLEVULINIC ACID;
AMINOLEVULINIC ACID METHYL ESTER;
BF 200;
PROTOPORPHYRIN;
REACTIVE OXYGEN METABOLITE;
UNCLASSIFIED DRUG;
ACTINIC KERATOSIS;
APPLICATION SITE EDEMA;
APPLICATION SITE ERYTHEMA;
APPLICATION SITE IRRITATION;
APPLICATION SITE PAIN;
APPLICATION SITE PRURITUS;
APPLICATION SITE REACTION;
DISEASE SEVERITY;
DRUG ABSORPTION;
DRUG APPROVAL;
DRUG CLEARANCE;
DRUG EFFICACY;
DRUG FORMULATION;
DRUG METABOLISM;
DRUG PENETRATION;
DRUG SAFETY;
DRUG TOLERABILITY;
ERYTHEMA;
FACE ACTINIC KERATOSIS;
GEL;
HEADACHE;
HEALING;
HUMAN;
HYPERALGESIA;
ILLUMINATION;
IMMUNOSUPPRESSIVE TREATMENT;
LOCAL SKIN REACTION;
NANOEMULSION;
NONHUMAN;
PARESTHESIA;
PHASE 3 CLINICAL TRIAL (TOPIC);
PHOTODYNAMIC THERAPY;
PHOTOTOXICITY;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RED LIGHT;
REMISSION;
REVIEW;
RISK ASSESSMENT;
RISK MANAGEMENT;
SCALP ACTINIC KERATOSIS;
SCAR;
SKIN EXFOLIATION;
SKIN INDURATION;
SKIN IRRITATION;
SKIN TIGHTNESS;
ADMINISTRATION, TOPICAL;
ADOLESCENT;
ADULT;
AGED;
AGED, 80 AND OVER;
AMINOLEVULINIC ACID;
FACE;
FEMALE;
GELS;
HUMANS;
KERATOSIS, ACTINIC;
MALE;
MIDDLE AGED;
PHOTOCHEMOTHERAPY;
PHOTOSENSITIZING AGENTS;
SCALP;
SURVIVAL RATE;
TREATMENT OUTCOME;
YOUNG ADULT;
|
|
EID: 84890338054
PISSN: 09546634
EISSN: 14711753
Source Type: Journal
DOI: 10.3109/09546634.2013.789474 Document Type: Review |
|
Times cited : (10)
|
|
References (5)
|
